Diuretic Selection Logic

Clinical meaning

Diuretic selection requires understanding where each drug class acts along the nephron and how site-of-action determines efficacy, electrolyte effects, and clinical indications.

1. Loop diuretics (furosemide, bumetanide, torsemide) act on the thick ascending limb of the loop of Henle by inhibiting the Na+/K+/2Cl- cotransporter (NKCC2). This site reabsorbs ~25% of filtered sodium, making loop diuretics the most POTENT diuretics available. They also impair the medullary concentration gradient (countercurrent multiplication), reducing the kidney's ability to concentrate urine. Effect: massive natriuresis and diuresis, calciuria (loop diuretics WASTE calcium — opposite of thiazides), hypokalemia, hypomagnesemia, metabolic alkalosis. Key pharmacokinetics: furosemide has variable oral bioavailability (~50%), short duration (6 hours); torsemide has more predictable absorption (~80%) and longer duration (12-16 hours).

2. Thiazide diuretics (hydrochlorothiazide, chlorthalidone, metolazone) act on the distal convoluted tubule by inhibiting the Na+/Cl- cotransporter (NCC). This site reabsorbs only ~5% of filtered sodium, so thiazides are LESS potent than loops. However, they have superior antihypertensive effect at lower doses due to additional vasodilatory properties. Effect: moderate natriuresis, hypocalciuria (thiazides RETAIN calcium — useful in calcium nephrolithiasis and osteoporosis), hypokalemia, hyperglycemia, hyperuricemia, hyperlipidemia (metabolic effects). Chlorthalidone has a longer duration (24-72 hours) and stronger evidence base for cardiovascular outcomes than HCTZ.

3. Potassium-sparing diuretics act on the collecting duct. Spironolactone and eplerenone are mineralocorticoid receptor antagonists (MRAs) that block aldosterone's action on principal cells, reducing ENaC-mediated sodium reabsorption and potassium secretion. Amiloride and triamterene directly block ENaC. Effect: mild natriuresis, potassium RETENTION (risk of hyperkalemia). MRAs have proven mortality benefit in HFrEF (RALES, EPHESUS trials).

Diagnosis & workup

Diagnostics & workup: - Serum electrolytes: sodium, potassium, chloride, bicarbonate, magnesium, calcium — baseline and 1-2 weeks after initiation or dose change; guides diuretic selection and monitors for adverse effects - Serum creatinine and eGFR: determines which diuretic classes are effective (thiazides lose efficacy below eGFR ~30; loop diuretics work at any GFR but may need higher doses); also monitors for diuretic-induced prerenal AKI - Uric acid level: baseline and periodic monitoring, especially with thiazide or loop diuretic therapy (both can precipitate gout through reduced uric acid excretion) - Spot urine sodium: <20 mEq/L suggests inadequate natriuretic response (diuretic resistance); >100 mEq/L suggests excessive diuresis or dietary sodium excess - Serum glucose and lipid panel: thiazides can worsen glucose tolerance and lipid profile — monitor in diabetic patients and those at metabolic risk - BNP/NT-proBNP in heart failure: trends guide diuretic dose adjustment (rising BNP suggests worsening congestion, declining BNP suggests effective decongestion) - Daily weights in hospitalized HF patients: most reliable indicator of fluid status change (1 kg = approximately 1 liter of fluid)

Risk factors: - Chronic kidney disease (loop diuretics maintain efficacy at low GFR, but thiazides lose efficacy below eGFR ~30 mL/min — except metolazone, which remains effective) - Heart failure (neurohormonal activation increases sodium retention, requiring higher diuretic doses; diuretic resistance is common) - Hepatic cirrhosis with ascites (secondary hyperaldosteronism — spironolactone is first-line; avoid excessive diuresis causing hepatorenal syndrome) - Electrolyte imbalances: pre-existing hypokalemia or hyperkalemia determines diuretic class selection (avoid potassium-wasting agents in hypokalemia; avoid potassium-sparing agents in hyperkalemia) - Concurrent use of ACE inhibitors/ARBs/MRAs with potassium-sparing diuretics (additive hyperkalemia risk — monitor potassium closely) - Gout or hyperuricemia (thiazides and loop diuretics increase uric acid levels by competing for organic acid secretion in the proximal tubule) - Diabetes mellitus (thiazides can worsen glucose tolerance through hypokalemia-mediated impairment of insulin secretion and direct effects on beta cells)

Clinical meaning

Your next step on FNP

Practice this topic

Review related lessons

FNP CAT

Diagnosis & workup

Management

Prescribing & monitoring

Takeaways

Your next step on FNP

Practice this topic

Review related lessons

FNP CAT

Clinical meaning

Practice questions for this topic

Your next step on FNP

Practice this topic

Review related lessons

FNP CAT

Diagnosis & workup

Practice questions for this topic

Your next step on FNP

Practice this topic

Review related lessons

FNP CAT